ICON plc

DUBLIN - Study Examines Impact of Regulatory Changes on Pharma Industry According to a report issued today, drug safety leaders in pharmaceutical and biotechnology companies recognise the need to increase resources, either internally or through partnerships, to comply with the safety regulations recently issued by the U.S.

DUBLIN - New Facility Part of Ambitious Expansion Plans at Central Manchester University Hospitals Foundation Trust Campus ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed a collaborative agreement with the Central Manchester University Hospitals Foundation (CMFT) to develop a purpose built translational medicine facility.

DUBLIN - Strategic Partnership Leverages ICON's Extensive European Capabilities ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed a strategic partnership with Eli Lilly and Company (NYSE: LLY) to manage the company's clinical trial site set up and monitoring in Europe for Lilly managed studies.